Assessment of the protective efficacy of Seasonal Malaria Chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine using case control studies, in Burkina Faso, Chad, The Gambia, Mali and Nigeria, 2015-2016

Résumé fourni par la source

Case-control studies were carried out in five of the seven countries implementing SMC through the ACCESS-SMC programme (Burkina Faso, Chad, Mali, Nigeria and The Gambia) in 2015 and 2016. Children presenting at study clinics with microscopically-confirmed clinical malaria were recruited as cases, and children living in the same community as the cases were recruited as controls. The history of SMC use was determined for both cases and controls by examining the SMC card, interviewing the mother/caregiver and checking drug delivery records for the village. A total of 2,185 cases with confirmed malaria and 4,370 controls were enrolled. In 2015, there were 252 cases in Mali and 226 cases in The Gambia, with 2 controls per case, and in 2016, 459 cases in Burkina Faso, 199 in Chad, 341 in Mali, 460 in Nigeria and 248 in The Gambia again with 2 controls per case. In matched analyses, matched on time and controlling for age, use of an insecticide-treated bed net and the caregiver’s socio-economic status, the efficacy of SMC over 28 days ranged from 63% to 98%. The average efficacy, from a random-effects meta-analysis of the individual studies, was 88% (95%CI 79%, 94%) over 28 days from treatment and 61% (95%CI 47% to 72%) 29 to 42 days post-treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.